Gilead Sciences signs Cognizant deal and Gilead Sciences stock gains 3.50 percent

Published on 10/07/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 product sales hit USD 7.60 billion, up 8.00 percent year over year. Gilead Sciences stock costs EUR 132.57 after EUR 128.09 on October 7, 2026.

Schwarzweiß-Reportage: Gilead Sciences Forscherin am Mikroskop im Biopharma-Labor — Gilead Sciences ISIN US3755581036 Schwarzweiß-Reportage Forscherin untersucht Zellkulturen am Mikroskop im Labor, Illustration mit AI erstellt.

Gilead Sciences stock (ISIN US3755581036) was trading at EUR 132.57 at Lang & Schwarz on October 7, 2026 at 4:01 p.m. CEST, plus 3.50 percent versus the prior close of EUR 128.09. According to Pharmaceutical Technology on October 7, 2026, Gilead Sciences signed a five-year agreement extension with Cognizant covering DevOps capabilities and selected agentic AI initiatives.

Five-year technology agreement

The agreement extends a collaboration that has supported Gilead's information technology infrastructure, software platforms and analytics for more than a decade, according to Pharmaceutical Technology. The expanded work is aimed at practical technology use cases rather than a disclosed acquisition or product transaction, keeping the financial impact of the arrangement unspecified in the published report.

For investors, the more measurable operating signal remains Gilead's second-quarter performance. In the second quarter of 2026, total product sales reached USD 7.60 billion, up 8.00 percent year over year, while base business sales rose 10.00 percent year over year, according to Yahoo Finance in its August 4, 2026 transcript.

HIV growth offsets cell therapy pressure

HIV sales were USD 5.70 billion in the second quarter of 2026, up 12.00 percent year over year, while PrEP sales exceeded USD 1.00 billion for the first time, according to Yahoo Finance. Trodelvy sales rose 26.00 percent year over year to USD 457.00 million, but cell therapy sales fell 14.00 percent to USD 417.00 million in the same period.

The contrast matters because the five-year Cognizant arrangement supports operating infrastructure while Gilead's commercial growth is concentrated in HIV and selected oncology products. The company also raised its full-year 2026 HIV sales growth expectation to 9.00-10.00 percent from 8.00 percent, according to Yahoo Finance.

Analyst caution meets stronger guidance

According to MarketBeat on October 1, 2026, Zacks Research cut its rating from Strong Buy to Hold on September 29, 2026. The same report said the analyst reduced the first-quarter 2028 earnings estimate to USD 2.14 per share from USD 2.15.

That caution sits alongside the latest operating evidence: Gilead's second-quarter revenue exceeded the USD 7.40 billion consensus cited by MarketBeat, reaching USD 7.80 billion. The competing signals leave HIV execution, cell therapy demand and the integration of recent acquisitions as the clearest operating markers.

Stock trades above prior close

Gilead Sciences was trading at EUR 132.57 at Lang & Schwarz on October 7, 2026 at 4:01 p.m. CEST, plus 3.50 percent versus the Lang & Schwarz prior close of EUR 128.09 on October 6, 2026. The primary listing is NASDAQ, where the finance quote showed USD 147.94 on October 7, 2026 at 2:05 p.m. UTC, with a 52-week range of USD 93.37 to USD 157.29.

The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.